Charles River Laboratories International, Inc. (CRL) Financial Ratios
28 years of historical data (1998–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
↓
12.73
↓-31% vs avg
5yr avg: 18.34
30Y Low7.9·High26.1
P/FCF
↓
16.87
↓-42% vs avg
5yr avg: 29.25
30Y Low9.0·High79.1
P/B Ratio
↓
2.80
↓-31% vs avg
5yr avg: 4.08
30Y Low1.5·High7.5
ROE
↓
-4.3%
↑-149% vs avg
5yr avg: 8.8%
30Y Low-110%·High58%
Debt/EBITDA
↓
3.36
↓-8% vs avg
5yr avg: 3.65
30Y Low0.0·High6.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Charles River Laboratories International, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 16.9x P/FCF, 42% below the 5-year average of 29.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8.7B | $10.1B | $9.6B | $12.2B | $11.2B | $19.4B | $12.6B | $7.6B | $5.5B | $5.3B | $3.7B |
| Enterprise Value | $11.6B | $12.9B | $12.1B | $15.0B | $14.0B | $22.3B | $14.6B | $9.4B | $7.0B | $6.3B | $4.8B |
| P/E Ratio → | -62.39 | — | 930.80 | 25.64 | 22.99 | 49.58 | 34.70 | 30.13 | 24.50 | 43.09 | 23.59 |
| P/S Ratio | 2.18 | 2.51 | 2.37 | 2.95 | 2.81 | 5.47 | 4.32 | 2.90 | 2.45 | 2.86 | 2.17 |
| P/B Ratio | 2.80 | 3.14 | 2.74 | 3.32 | 3.70 | 7.48 | 5.90 | 4.56 | 4.15 | 5.00 | 4.28 |
| P/FCF | 16.87 | 19.47 | 19.16 | 33.29 | 37.91 | 36.42 | 33.28 | 22.30 | 18.43 | 22.73 | 15.03 |
| P/OCF | 11.86 | 13.68 | 13.08 | 17.78 | 18.04 | 25.47 | 23.14 | 15.78 | 12.58 | 16.81 | 12.25 |
P/E links to full P/E history page with 30-year chart
CRL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Charles River Laboratories International, Inc.'s enterprise value stands at 12.7x EBITDA, 31% below its 5-year average of 18.3x. The Healthcare sector median is 14.2x, placing the stock at a 10% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.22 | 3.00 | 3.62 | 3.53 | 6.31 | 4.99 | 3.58 | 3.11 | 3.39 | 2.84 |
| EV / EBITDA | 12.73 | 14.21 | 20.61 | 16.05 | 14.71 | 26.12 | 21.83 | 17.07 | 14.29 | 15.01 | 13.10 |
| EV / EBIT | 22.84 | 25.49 | 55.33 | 20.83 | 20.58 | 40.28 | 27.32 | 25.70 | 20.41 | 19.27 | 19.04 |
| EV / FCF | — | 24.97 | 24.20 | 40.92 | 47.61 | 41.99 | 38.36 | 27.55 | 23.41 | 26.93 | 19.63 |
CRL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Charles River Laboratories International, Inc. earns an operating margin of 12.6%. Operating margins have compressed from 14.9% to 12.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -4.3% indicates the company is currently destroying shareholder equity. ROIC of 6.3% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.5% | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% | 36.6% | 37.1% | 37.7% | 38.3% |
| Operating Margin | 12.6% | 12.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% |
| Net Profit Margin | -3.6% | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -4.3% | -4.3% | 0.3% | 14.2% | 17.3% | 16.5% | 19.1% | 16.8% | 18.8% | 12.9% | 19.1% |
| ROA | -2.0% | -2.0% | 0.1% | 6.0% | 6.6% | 6.2% | 7.2% | 5.9% | 6.7% | 4.4% | 6.5% |
| ROIC | 6.3% | 6.3% | 2.7% | 7.5% | 8.5% | 9.2% | 8.6% | 8.4% | 10.2% | 10.8% | 10.2% |
| ROCE | 8.1% | 8.1% | 3.3% | 9.0% | 10.4% | 11.1% | 10.0% | 9.6% | 11.5% | 12.1% | 11.8% |
CRL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Charles River Laboratories International, Inc. carries a Debt/EBITDA ratio of 3.4x, which is moderately leveraged (roughly in line with the sector average of 3.2x). Net debt stands at $2.9B ($3.1B total debt minus $214M cash). Interest coverage of 4.7x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.95 | 0.95 | 0.78 | 0.84 | 1.02 | 1.24 | 1.01 | 1.22 | 1.27 | 1.08 | 1.45 |
| Debt / EBITDA | 3.36 | 3.36 | 4.62 | 3.29 | 3.24 | 3.75 | 3.24 | 3.69 | 3.44 | 2.73 | 3.39 |
| Net Debt / Equity | — | 0.89 | 0.72 | 0.76 | 0.95 | 1.14 | 0.90 | 1.07 | 1.12 | 0.92 | 1.31 |
| Net Debt / EBITDA | 3.13 | 3.13 | 4.29 | 3.00 | 3.00 | 3.47 | 2.89 | 3.25 | 3.05 | 2.34 | 3.07 |
| Debt / FCF | — | 5.50 | 5.04 | 7.64 | 9.71 | 5.57 | 5.08 | 5.25 | 4.99 | 4.20 | 4.60 |
| Interest Coverage | 4.74 | 4.74 | 1.74 | 5.25 | 11.51 | 7.50 | 6.17 | 5.99 | 5.42 | 10.97 | 9.05 |
CRL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.29x means Charles River Laboratories International, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.52x to 1.29x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.29 | 1.29 | 1.41 | 1.52 | 1.32 | 1.23 | 1.43 | 1.44 | 1.61 | 1.78 | 1.53 |
| Quick Ratio | 1.02 | 1.02 | 1.13 | 1.16 | 1.08 | 1.04 | 1.21 | 1.21 | 1.38 | 1.54 | 1.31 |
| Cash Ratio | 0.19 | 0.19 | 0.20 | 0.26 | 0.21 | 0.24 | 0.27 | 0.34 | 0.35 | 0.35 | 0.27 |
| Asset Turnover | — | 0.56 | 0.54 | 0.50 | 0.52 | 0.50 | 0.53 | 0.56 | 0.59 | 0.63 | 0.62 |
| Inventory Turnover | 9.33 | 9.33 | 9.76 | 6.91 | 9.83 | 11.07 | 9.96 | 10.35 | 11.15 | 10.06 | 10.83 |
| Days Sales Outstanding | — | 64.44 | 64.97 | 68.98 | 69.07 | 67.06 | 77.11 | 71.58 | 76.06 | 84.49 | 79.03 |
CRL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Charles River Laboratories International, Inc. returns 4.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.1% | 3.9% | 4.4% | 2.0% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% |
| FCF Yield | 5.9% | 5.1% | 5.2% | 3.0% | 2.6% | 2.7% | 3.0% | 4.5% | 5.4% | 4.4% | 6.7% |
| Buyback Yield | 4.1% | 3.6% | 1.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 2.0% | 0.3% |
| Total Shareholder Yield | 4.1% | 3.6% | 1.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 2.0% | 0.3% |
| Shares Outstanding | — | $50M | $52M | $51M | $51M | $51M | $51M | $50M | $49M | $49M | $48M |
Peer Comparison
Compare CRL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRLYou | $9B | -62.4 | 12.7 | 16.9 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 MEDP | $13B | 29.8 | 22.7 | 19.1 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 ICLR | $11B | 48.5 | 9.8 | 12.5 | 26.4% | 12.3% | 2.5% | 6.2% | 2.5 |
 PRA | $1B | 24.8 | 19.4 | — | 39.4% | 6.6% | 4.0% | 3.2% | 5.1 |
 LBRT | $5B | 31.3 | 9.2 | 320.0 | 11.4% | 2.0% | 7.3% | 2.3% | 1.5 |
 LH | $21B | 24.3 | 12.6 | 17.4 | 26.8% | 10.9% | 10.5% | 7.8% | 3.3 |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 HALO | $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 TMO | $172B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 28 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CRL — Frequently Asked Questions
Quick answers to the most common questions about buying CRL stock.
What is Charles River Laboratories International, Inc.'s P/E ratio?
Charles River Laboratories International, Inc.'s current P/E ratio is -62.4x. The historical average is 27.9x.
What is Charles River Laboratories International, Inc.'s EV/EBITDA?
Charles River Laboratories International, Inc.'s current EV/EBITDA is 12.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.3x.
What is Charles River Laboratories International, Inc.'s ROE?
Charles River Laboratories International, Inc.'s return on equity (ROE) is -4.3%. The historical average is 7.1%.
Is CRL stock overvalued?
Based on historical data, Charles River Laboratories International, Inc. is trading at a P/E of -62.4x. Compare with industry peers and growth rates for a complete picture.
What are Charles River Laboratories International, Inc.'s profit margins?
Charles River Laboratories International, Inc. has 30.5% gross margin and 12.6% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Charles River Laboratories International, Inc. have?
Charles River Laboratories International, Inc.'s Debt/EBITDA ratio is 3.4x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.